HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Aptose Biosciences (NASDAQ:APTO) with a maintained price target of $23.
March 27, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptose Biosciences receives a maintained Buy rating and $23 price target from HC Wainwright & Co.
The reaffirmation of a Buy rating and a significant price target suggests a strong positive outlook on Aptose Biosciences by HC Wainwright & Co. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100